Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
| ▸ | BRS3 | P32247 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4827917 | 1.00 | NAMPT (0.47) | NAMPTCYP17A1BCHEACHERAB9A | |
| SCHEMBL30114700 | 0.88 | NAMPT (0.47) | NAMPTCYP17A1RAB9AMETAP1BRS3 | |
| SCHEMBL18522430 | 0.86 | NAMPT (0.50) | NAMPTCYP17A1RAB9AMETAP1BRS3 | |
| SCHEMBL27693409 | 0.85 | RAB9A (0.44) | NAMPTCYP17A1BCHEACHERAB9A | |
| SCHEMBL1128597 | 0.84 | BCHE (0.49) | BCHEACHERAB9ANPC1 | |
| SCHEMBL2107971 | 0.83 | NAMPT (0.48) | NAMPTCYP17A1RAB9AMETAP1BRS3 | |
| SCHEMBL3666785 | 0.83 | NAMPT (0.48) | NAMPTCYP17A1RAB9AMETAP1BRS3 | |
| SCHEMBL5746021 | 0.82 | NAMPT (0.47) | NAMPTCYP17A1RAB9A | |
| SCHEMBL741240 | 0.82 | NAMPT (0.47) | NAMPTCYP17A1RAB9AMETAP1BRS3 | |
| SCHEMBL15039524 | 0.82 | CYP17A1 (0.55) | NAMPTCYP17A1RAB9AMETAP1BRS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12448379-B2 | Wild type kit inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2025-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448379-B2 | Wild type kit inhibitors | KIT, TNK1, TNNI3K | NAMPT 2003/4885CYP17A1 1372/4885BCHE 2804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.